TrialCancer2016

Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma.

Robert Z Orlowski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.